References
Pabst G, Jaeger H (1990) Review of methods and criteria for the evaluation of bioquivalence studies. Eur J Clin Pharmacol 38: 5–10
Selwyn MR, Hall NR (1984) On Bayesian methods for bioequivalence. Biometrics 40: 1103–1108
Flühler H, Grieve AP, Mandallaz D, Mau J, Moser HA (1983) Bayesian approach to bioquivalence assessment: An example. J Pharmaceut Sci 72: 1178–1181
Anderson S, Hauck WW (1990) Consideration of individual bioequivalence. J Pharmacokin Biopharmaceut 18: 259–273
Steinijans VW, Hauschke D (1990) Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 105–110
Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley and Sons, New York
Hauschke D, Steinijans VW, Diletti E (1990) A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 72–78
Koch GG (1972) The use of nonparametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577–584
Gardner MJ, Altman DG (1986) Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 292: 746–750
Rodda BE, Davis LD (1980) Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 28: 247–252
Frick H (1987) On level and power of Anderson and Hauck's procedure for testing equivalence in comparative bioavailability. Commun Statist Theory Meth 16: 2771–2778
Rocke DM (1984) On testing for bioequivalence. Biometrics 40: 225–230
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pabst, G. Reply to the comments of Dr. Grieve. Eur J Clin Pharmacol 40, 202–203 (1991). https://doi.org/10.1007/BF00280081
Issue Date:
DOI: https://doi.org/10.1007/BF00280081